Insmed Inc

Insmed management has raised the peak-sales estimate for its three lead programs to more than $14 billion, a 75% increase from the prior figure. More than $7 billion of that total is attributed to the already-launched bronchiectasis drug BRINSUPRI, which generated $309.2 million in its third full quarter, and more than $1 billion to ARIKAYCE. The remaining more than $6 billion depends on TPIP, an inhaled treatment for pulmonary arterial hypertension and other lung conditions, which is still in Phase III trials for only two of its four target indications and assumes approval in all four as well as breaking orphan status in one. The company ended June with about $1.2 billion in cash and marketable securities, which management says funds the business to cash flow positivity in 2027 without a current intention to raise capital.

Insmed shares surged 33.16 percent to $131.85 after the biopharmaceutical company reported a sharply narrower second-quarter loss, strong product revenue growth, and raised its full-year outlook for Brinsupri. Second-quarter net loss narrowed to $13.24 million, or $0.06 per share, from $321.69 million, or $1.70 per share, a year earlier. Net product revenue nearly quadrupled to $425.49 million, driven by Brinsupri revenue of $309.2 million, up 49 percent sequentially, and Arikayce revenue of $116.3 million, up 8 percent year over year. The company raised its 2026 Brinsupri revenue guidance to $1.25 billion to $1.40 billion while reaffirming Arikayce guidance of $450 million to $470 million.

Zacks Equity Research has identified five biotech companies that are expected to beat earnings estimates in their upcoming second-quarter 2026 reports. The stocks are Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed, and Agios Pharmaceuticals, each combining a positive Earnings ESP with a Zacks Rank of 1, 2, or 3. Harmony Biosciences carries an Earnings ESP of +14.14% and a Zacks Rank #1, with a consensus estimate of 97 cents per share, and reports on August 4 before the open. Acadia Pharmaceuticals has an Earnings ESP of +25.00% and a Zacks Rank #2, with a consensus of 6 cents per share, reporting after the close on August 4. Biogen shows an Earnings ESP of +220.79% and a Zacks Rank #3, with a consensus of 94 cents per share, and reports on July 29 before the open. Insmed has an Earnings ESP of +22.32% and a Zacks Rank #3, with a consensus loss of 69 cents per share, reporting on August 6 before the open. Agios Pharmaceuticals has an Earnings ESP of +12.67% and a Zacks Rank #3, with a consensus loss of $1.86 per share, and reports on July 30 before the open.

Billionaire investor Stanley Druckenmiller's Duquesne Family Office disclosed its top five long positions, spanning a Mexican discount grocer, two biotech firms, a semiconductor giant, and an Argentine oil producer. The largest holding is BBB Foods, a hard-discount grocer in Mexico that grew revenue 33.44% year-over-year to roughly Ps.22.86 billion in Q1 2026, with same-store sales up 16.0%. Insmed, a rare-disease pharma, saw total revenue surge 229.6% to $305.96 million, driven by its newly launched bronchiectasis drug BRINSUPRI which contributed $207.90 million in its first full quarter. Taiwan Semiconductor Manufacturing posted Q2 2026 EPS of $4.31, beating consensus by 10.89%, on revenue of $40.20 billion, up 36.0% year-over-year. Natera, a precision-medicine company, processed over one million tests in a single quarter for the first time, with Q1 2026 revenue reaching $696.64 million, a 38.8% increase. YPF, Argentina's state-backed energy firm, swung to a $409 million net profit in Q1 2026 as shale oil production hit 205 kbbl/d, up 39% year-over-year, and lifting costs fell 42%, with its VMOS export pipeline targeting first oil in January 2027.

The healthcare sector saw multiple U.S. FDA approvals, including Novartis’ Fabhalta for IgA nephropathy and Merck’s LIPFENDRA for hypercholesterolemia, alongside Eli Lilly’s $2.8 billion acquisition of AtaiBeckley. Novartis received traditional FDA approval for Fabhalta as the first complement inhibitor for adults with primary IgAN at risk of progression, while Merck won approval for LIPFENDRA, the first once-daily oral PCSK9 inhibitor, which cut LDL-C by up to 59% in the Phase 3 CORALreef trial. Eli Lilly agreed to acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash plus up to $2.50 per share in a contingent value right, with the upfront cash consideration of approximately $2.8 billion and the CVR representing an additional potential value of approximately $1.0 billion. Other notable developments included Veradermics reporting positive Phase 2 results for its oral minoxidil formulation VDPHL01 in women with pattern hair loss, where a 4.5 mg once-daily dose led to an average increase of 22.7 hairs per square centimetre, and Insmed announcing encouraging 12-month data for its treprostinil palmitil inhalation powder in pulmonary arterial hypertension.

Insmed announced positive 12-month data from the ongoing open-label extension study of treprostinil palmitil inhalation powder, or TPIP, in patients with pulmonary arterial hypertension. The non-placebo-controlled trial showed sustained improvement across all efficacy endpoints and no new safety signals. At 12 weeks, the TPIP Continued group had a mean 6-minute walk distance improvement of 55.7 meters from baseline, while the Placebo Crossed group improved by 54.1 meters. NT-proBNP levels fell roughly 60% in both groups, and over 78% of patients achieved WHO Functional Class I or II. These findings support the launch of PALM-PAH, a Phase 3 randomized, double-blind, placebo-controlled trial of once-daily TPIP over 24 months.

TimesSquare Capital Management's U.S. Mid Cap Growth Strategy added to its position in Insmed during the first quarter of 2026, citing strong uptake of the company's newly approved lung-disease therapy Brinsupri. The strategy noted that Brinsupri's launch is well ahead of expectations and remains the primary growth driver, with projected 2026 sales of $1 billion, while Arikayce sales came in below Street estimates. Insmed shares fell 6% in the quarter, closing at $106.62 on June 30 with a market capitalization of $23.11 billion. The strategy, which declined 7.72% net versus a 6.35% drop for the Russell Midcap Growth Index, continues to favor health care companies offering novel therapies for unmet needs.

Mizuho maintained an Outperform rating on Insmed Incorporated and lowered its price target to $192 from $202, citing a buying opportunity after a 29% share decline since the company's first-quarter report. The firm expressed confidence in Insmed and its BRINSUPRI product, calling the recent shift in investor sentiment shocking. Separately, Insmed appointed Samuele Butera as Senior Vice President and General Manager, Global Respiratory, to lead the respiratory therapeutic area and support the launch of BRINSUPRI, the potential label expansion of ARIKAYCE, and the development of the TPIP program.

The European Multicentre Bronchiectasis Audit and Research Collaboration, EMBARC, announced its intention to collaborate with Insmed on a long-term, open-label, single-arm interventional study evaluating the disease modification potential of brensocatib 25 mg in bronchiectasis. The study plans to enroll approximately 3,000 patients across the United Kingdom, Spain, Germany, Belgium, France, and Italy over three years. It aims to deepen understanding of long-term brensocatib use and whether earlier, upstream treatment can alter the disease trajectory, building on ASPEN trial data that showed reduced exacerbation frequency and slowed lung function decline. Lead investigator James Chalmers of the University of Oxford said the study could help shape future bronchiectasis treatment. Insmed's Chief Medical Officer Martina Flammer noted the collaboration reflects a commitment to transformative research in a large, heterogeneous population.

Insmed Incorporated has appointed Samuele Butera as Senior Vice President, General Manager, Global Respiratory, effective today. In this new role, Mr. Butera will lead the company's Respiratory Therapeutic Area, reporting to Chair and CEO Will Lewis and serving on the Executive Committee. He joins from Johnson & Johnson, where he most recently served as President of Pulmonary Hypertension & Retina, overseeing a multi-billion-dollar business unit and the launch of OPSYNVI. His prior experience includes senior roles at Novartis, where he led the global launch of KYMRIAH, the first CAR-T therapy, and earlier positions at McKinsey & Company, Goldman Sachs, and the United Nations. Insmed stated that Mr. Butera's commercial expertise will be instrumental as the company continues the launch of BRINSUPRI, pursues a potential label expansion for ARIKAYCE, and advances its TPIP development program.